[HTML][HTML] Vaccine adjuvants: from 1920 to 2015 and beyond
A Di Pasquale, S Preiss, F Tavares Da Silva, N Garçon - Vaccines, 2015 - mdpi.com
The concept of stimulating the body’s immune response is the basis underlying vaccination.
Vaccines act by initiating the innate immune response and activating antigen presenting …
Vaccines act by initiating the innate immune response and activating antigen presenting …
[HTML][HTML] The how's and what's of vaccine reactogenicity
…, G Del Giudice, AM Didierlaurent, F Tavares Da Silva - npj Vaccines, 2019 - nature.com
Reactogenicity represents the physical manifestation of the inflammatory response to vaccination,
and can include injection-site pain, redness, swelling or induration at the injection site, …
and can include injection-site pain, redness, swelling or induration at the injection site, …
[HTML][HTML] Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled …
…, LD Sher, J Smith, F Tavares-Da-Silva… - The Lancet Infectious …, 2021 - thelancet.com
Background CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a
baculovirus expression system being developed against SARS-CoV-2. We present interim …
baculovirus expression system being developed against SARS-CoV-2. We present interim …
[HTML][HTML] Stillbirth: case definition and guidelines for data collection, analysis, and presentation of maternal immunization safety data
FT Da Silva, B Gonik, M McMillan, C Keech, S Dellicour… - Vaccine, 2016 - ncbi.nlm.nih.gov
Disclaimer: The findings, opinions and assertions contained in this consensus document
are those of the individual scientific professional members of the working group. They do not …
are those of the individual scientific professional members of the working group. They do not …
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2 …
…, S Ramirez, A Said, F Tavares-Da-Silva… - The Lancet Infectious …, 2022 - thelancet.com
Background We evaluated our SARS-CoV-2 prefusion spike recombinant protein vaccine (CoV2
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
preS dTM) with different adjuvants, unadjuvanted, and in a one-injection and two-…
[HTML][HTML] Vaccine safety evaluation: practical aspects in assessing benefits and risks
A Di Pasquale, P Bonanni, N Garçon, LR Stanberry… - Vaccine, 2016 - Elsevier
Vaccines are different from most medicines in that they are administered to large and mostly
healthy populations including infants and children, so there is a low tolerance for potential …
healthy populations including infants and children, so there is a low tolerance for potential …
[HTML][HTML] Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized …
…, L Schuerman, LD Sher, F Tavares-Da-Silva… - …, 2023 - thelancet.com
Background In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680),
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
we evaluated prototype (D614) and Beta (B.1.351) variant recombinant spike protein …
[HTML][HTML] Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial
G Leroux-Roels, A Marchant, J Levy, P Van Damme… - Clinical …, 2016 - Elsevier
Immunogenicity and safety of different adjuvants combined with a model antigen (HBsAg)
were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with …
were compared. Healthy HBV-naïve adults were randomized to receive HBs adjuvanted with …
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
N Lecrenier, P Beukelaers, R Colindres… - Expert review of …, 2018 - Taylor & Francis
Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix,
RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its …
RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its …
[HTML][HTML] Safety of AS03-adjuvanted influenza vaccines: A review of the evidence
Clinical and post-licensure data have demonstrated that AS03-adjuvanted inactivated split
virion vaccines, many with reduced antigen content, are effective against influenza infection. …
virion vaccines, many with reduced antigen content, are effective against influenza infection. …